Squamous cell carcinoma is a major type of
cancer in the lung. While several therapeutic target molecules for
lung adenocarcinoma have been identified, little is known about lung
squamous cell carcinoma (LSCC). We recently reported that
CD271 (
p75 neurotrophin receptor) serves as a marker for
tumor initiation and is a key regulator of cell proliferation in
hypopharyngeal squamous cell carcinoma. In this study, we found that
CD271 was also expressed in
squamous cell carcinoma, but not in
adenocarcinoma, of several tissues, including the lung, and the expression of
CD271 was associated with a poor prognosis in LSCC. To examine
CD271's role in LSCC, we established xenograft cell lines from LSCC patients. Within the sorted live LSCC cell population, the CD271high cells were primarily cycling through the G2/M phase, while the CD271low cells were mostly in the G0 phase.
CD271 knockdown in the LSCC cells completely suppressed their proliferation and
tumor-formation capability, and increased their cell-cycle arrest in the G0 phase. In the CD271-knockdown cells, ERK-phosphorylation was decreased, while no change was observed in the IκBα-phosphorylation, p65-phosphorylation, or Akt-phosphorylation. Treatment with the
MEK inhibitor
U0126 decreased the LSCC cells' proliferation capability. Microarray analysis revealed that
CD271 knockdown attenuated the RAS-related pathways. The knockdown of TrkB, which forms a heterodimer with
CD271 and accelerates its downstream signaling, partially inhibited the LSCC cell proliferation. These results indicated that LSCC exclusively depends on
CD271 for cell proliferation, in part through ERK-signaling activation, and
CD271 is a promising target for LSCC
therapy.